Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor




Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk’s Wegovy oral weight-loss drug.


Leave a Reply

Your email address will not be published. Required fields are marked *